Novartis AG
Utility Patent Applications
Last updated:
List of all Novartis AG patents 676 in total
| Status | Patent |
|---|---|
Application | Utility: SOLID FORMS OF N-(4-FLUORO-3-(6-(3-METHYLPYRIDIN-2-YL)-[1,2,4]TRIAZOLO[1,5-A]PYRIMIDIN-2- -YL)PHENYL)-2,4-DIMETHYLOXAZOLE-5-CARBOXAMIDE Filling date: 23 Sep 2025 Issue date: 10 Feb 2022 |
Application | Utility: ORGANIC COMPOUNDS Filling date: 23 Sep 2025 Issue date: 3 Feb 2022 |
Application | Utility: SYRINGE Filling date: 23 Sep 2025 Issue date: 3 Feb 2022 |
Application | Utility: Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumors Filling date: 23 Sep 2025 Issue date: 3 Feb 2022 |
Application | Utility: N-(pyridin-2-ylsulfonyl)cyclopropanecarboxamide Derivatives and their Use in the Treatment of Disease Filling date: 23 Sep 2025 Issue date: 3 Feb 2022 |
Application | Utility: 6-HYDROXY-8-OXATRICYCLO[3.2.1.02,4]OCTANE-2-CARBOXAMIDE DERIVATIVES FOR INDUCING CHONDROGENESIS FOR TREATING JOINT DAMAGE Filling date: 23 Sep 2025 Issue date: 3 Feb 2022 |
Application | Utility: ANTI-BETACELLULIN ANTIBODIES, FRAGMENTS THEREOF, AND MULTI-SPECIFIC BINDING MOLECULES Filling date: 23 Sep 2025 Issue date: 27 Jan 2022 |
Application | Utility: USE OF IL-1BETA BINDING ANTIBODIES Filling date: 23 Sep 2025 Issue date: 27 Jan 2022 |
Application | Utility: REVERSAL BINDING AGENTS FOR ANTI-FACTOR XI/XIA ANTIBODIES AND USES THEREOF Filling date: 23 Sep 2025 Issue date: 27 Jan 2022 |
Application | Utility: CYCLIC PEPTIDES AS PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) INHIBITORS FOR THE TREATMENT OF METABOLIC DISORDERS Filling date: 23 Sep 2025 Issue date: 27 Jan 2022 |
Application | Utility: LPL-GPIHBP1 FUSION POLYPEPTIDES Filling date: 23 Sep 2025 Issue date: 27 Jan 2022 |
Application | Utility: Multi-Copy Gene Protein Expression System Filling date: 23 Sep 2025 Issue date: 27 Jan 2022 |
Application | Utility: METHODS OF USING FACTOR B INHIBITORS Filling date: 23 Sep 2025 Issue date: 20 Jan 2022 |
Application | Utility: SIP MODULATOR IMMEDIATE RELEASE DOSAGE REGIMEN Filling date: 23 Sep 2025 Issue date: 20 Jan 2022 |
Application | Utility: COMBINATION OF A MCL-1 INHIBITOR AND MIDOSTAURIN, USES AND PHARMACEUTICAL COMPOSITIONS THEREOF Filling date: 23 Sep 2025 Issue date: 20 Jan 2022 |
Application | Utility: TREATMENT OF AUTOIMMUNE DISEASE IN A PATIENT RECEIVING ADDITIONALLY A BETA-BLOCKER Filling date: 23 Sep 2025 Issue date: 13 Jan 2022 |
Application | Utility: LFA-1 INHIBITOR FORMULATIONS Filling date: 23 Sep 2025 Issue date: 6 Jan 2022 |
Application | Utility: PHARMACEUTICAL COMPOSITIONS OF LIPOIC ACID CHOLINE ESTER SALTS AND METHODS OF TREATMENT USING SAME Filling date: 23 Sep 2025 Issue date: 23 Dec 2021 |
Application | Utility: APPLICATION UNLOCK USING A CONNECTED PHYSICAL DEVICE AND TRANSFER OF DATA THEREBETWEEN Filling date: 23 Sep 2025 Issue date: 23 Dec 2021 |
Application | Utility: METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-4,5,6,7-TETRAHYDRO-1H-CYCLOPENT- A[B]PYRIDINE-3-CARBOXYLATE AND METHYL (R)-2-(FLUOROMETHYL)-5-OXO-4-PHENYL-1,4,5,7-TETRAHYDROFURO[3,4-B]PYRIDINE- -3-CARBOXYLATE AS CAV1.2 ACTIVATORS Filling date: 23 Sep 2025 Issue date: 23 Dec 2021 |
Application | Utility: METHOD FOR REDUCING THE RISK OF A CARDIOVASCULAR EVENT WITH CONJUGATED ANTISENSE COMPOUNDS TARGETING APO(A) Filling date: 23 Sep 2025 Issue date: 23 Dec 2021 |
Application | Utility: NLRP MODULATORS Filling date: 23 Sep 2025 Issue date: 23 Dec 2021 |
Application | Utility: BIOMARKERS FOR EVALUATING CAR-T CELLS TO PREDICT CLINICAL OUTCOME Filling date: 23 Sep 2025 Issue date: 23 Dec 2021 |
Application | Utility: Nucleic Acids Encoding FGF21-Fc Fusion Proteins Filling date: 23 Sep 2025 Issue date: 16 Dec 2021 |
Application | Utility: METHODS FOR TREATING LIVER DISORDERS USING FXR AGONISTS Filling date: 23 Sep 2025 Issue date: 16 Dec 2021 |
Application | Utility: METHYL 2-METHYL-5-OXO-1,4,5,7-TETRADHYDROFURO[3,4-b]PYRIDINE-3-CARBOXYLATE COMPOUNDS AS CAV1.2 ACTIVATORS Filling date: 23 Sep 2025 Issue date: 16 Dec 2021 |
Application | Utility: PROTEIN KINASE C INHIBITORS AND METHODS OF THEIR USE Filling date: 23 Sep 2025 Issue date: 16 Dec 2021 |
Application | Utility: PHARMACEUTICAL COMBINATIONS Filling date: 23 Sep 2025 Issue date: 16 Dec 2021 |
Application | Utility: The use of a H3R inverse agonist for the treatment of excessive daytime sleepiness associated with parkinson's disease (PD) Filling date: 23 Sep 2025 Issue date: 9 Dec 2021 |
Application | Utility: COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES Filling date: 23 Sep 2025 Issue date: 2 Dec 2021 |
Application | Utility: ADENO-ASSOCIATED VIRUS VIRIONS WITH VARIANT CAPSIDS AND METHODS OF USE THEREOF Filling date: 23 Sep 2025 Issue date: 2 Dec 2021 |
Application | Utility: CRYSTALLINE FORM OF LNP023 Filling date: 23 Sep 2025 Issue date: 2 Dec 2021 |
Application | Utility: Use of IL-1 beta Binding Antibodies Filling date: 23 Sep 2025 Issue date: 2 Dec 2021 |
Application | Utility: N-AZASPIROCYCLOALKANE SUBSTITUTED N-HETEROARYL COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 Filling date: 23 Sep 2025 Issue date: 2 Dec 2021 |
Application | Utility: COVALENT TARGETING OF E3 LIGASES Filling date: 23 Sep 2025 Issue date: 2 Dec 2021 |
Application | Utility: USE OF CANAKINUMAB Filling date: 23 Sep 2025 Issue date: 2 Dec 2021 |
Application | Utility: MYOSTATIN, ACTIVIN OR ACTIVIN RECEPTOR ANTAGONISTS FOR USE IN TREATING OBESITY AND RELATED CONDITIONS Filling date: 23 Sep 2025 Issue date: 25 Nov 2021 |
Application | Utility: PHARMACEUTICAL COMBINATIONS Filling date: 23 Sep 2025 Issue date: 25 Nov 2021 |
Application | Utility: FXR AGONISTS FOR THE TREATMENT OF LIVER DISEASES Filling date: 23 Sep 2025 Issue date: 25 Nov 2021 |
Application | Utility: COMPOSITIONS AND METHODS FOR ANTIBODIES TARGETING EPO Filling date: 23 Sep 2025 Issue date: 18 Nov 2021 |
Application | Utility: CYCLODEXTRIN-BASED FORMULATION OF A BCL-2 INHIBITOR Filling date: 23 Sep 2025 Issue date: 18 Nov 2021 |
Application | Utility: ISOXAZOLE CARBOXAMIDE COMPOUNDS AND USES THEREOF Filling date: 23 Sep 2025 Issue date: 18 Nov 2021 |
Application | Utility: MANUFACTURE OF COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF SHP2 Filling date: 23 Sep 2025 Issue date: 18 Nov 2021 |
Application | Utility: COMPOUNDS AND COMPOSITIONS FOR INDUCING CHONDROGENESIS Filling date: 23 Sep 2025 Issue date: 11 Nov 2021 |
Application | Utility: ANTIBODY CONJUGATES COMPRISING TOLL-LIKE RECEPTOR AGONIST Filling date: 23 Sep 2025 Issue date: 11 Nov 2021 |
Application | Utility: TUMOR MUTATION BURDEN ALONE OR IN COMBINATION WITH IMMUNE MARKERS AS BIOMARKERS FOR PREDICTING RESPONSE TO TARGETED THERAPY Filling date: 23 Sep 2025 Issue date: 11 Nov 2021 |
Application | Utility: CD19 CHIMERIC ANTIGEN RECEPTOR (CAR) AND CD22 CAR COMBINATION THERAPIES Filling date: 23 Sep 2025 Issue date: 11 Nov 2021 |
Application | Utility: PROCESS OF MANUFACTURE OF A COMPOUND FOR INHIBITING THE ACTIVITY OF SHP2, AS WELL AS PRODUCTS RESULTING FROM ACID ADDITION Filling date: 23 Sep 2025 Issue date: 11 Nov 2021 |
Application | Utility: Fused Tricyclic Pyrazolo-Dihydropyrazinyl-Pyridone Compounds as Antivirals Filling date: 23 Sep 2025 Issue date: 11 Nov 2021 |
Application | Utility: METHODS FOR TREATING OCULAR DISEASES Filling date: 23 Sep 2025 Issue date: 4 Nov 2021 |
Showing 100 to 150 of 676 patents.